Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0006632003
Wed, 17.05.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 17, 2023
MorphoSys AG Reports Outcome of Annual General Meeting 2023
All Proposed Resolutions Approved
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual Genera [ … ]
Wed, 17.05.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 17, 2023
MorphoSys AG Reports Outcome of Annual General Meeting 2023
All Proposed Resolutions Approved
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual Genera [ … ]
Thu, 11.05.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 11, 2023
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the latest data on multiple pipeline therapies will be presented during the American Society of Clinical Oncology (ASCO [ … ]
Thu, 11.05.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 11, 2023
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the latest data on multiple pipeline therapies will be presented during the American Society of Clinical Oncology (ASCO [ … ]
Wed, 03.05.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 03, 2023
MorphoSys AG Reports First Quarter 2023 Financial Results
Monjuvi® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023
Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2 [ … ]
Wed, 03.05.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 03, 2023
MorphoSys AG Reports First Quarter 2023 Financial Results
Monjuvi® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023
Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2 [ … ]
Thu, 27.04.2023
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, April 27, 2023
Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT).
MorphoSys' Management team will host a [ … ]
Thu, 27.04.2023
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, April 27, 2023
Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT).
MorphoSys' Management team will host a [ … ]
Sun, 16.04.2023
MorphoSys AG
Media Release
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual M [ … ]
Sun, 16.04.2023
MorphoSys AG
Media Release
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual M [ … ]